Changes in Treatment Patterns and Their Influence on the Outcome of Systemic Sclerosis-interstitial Lung Disease (SSc-ILD) Patients: An EUSTAR Analysis

被引：0
|
作者：
Campochiaro, Corrado [1 ]
Truchetet, Marie-Elise [2 ]
Vonk, Madelon [3 ]
Cuomo, Giovanna [4 ]
Ananieva, Lidia P. [5 ]
Hachulla, Eric [6 ]
Smith, Vanessa [7 ]
Gheorghiu, Ana Maria [8 ]
Becvar, Radim [9 ]
Hunzelmann, Nicolas [10 ]
Furst, Daniel [11 ,12 ]
Ortiz-Santamaria, Vera
Carreira, Patricia [13 ]
Del Galdo, Francesco [14 ]
Cerinic, Marco Matucci [15 ]
Hoffmann-Vold, Anna Maria [16 ]
机构：
[1] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Unit Immunol Rheumatol Allergy & Rare Disease, Milan, Italy
[2] Bordeaux Univ Hosp, Bordeaux, France
[3] Radboud Univ Nijmegen, Nijmegen Med Ctr, Nijmegen, Netherlands
[4] Luigi Vanvitelli Univ Campania, Dept Precis Med, Naples, Italy
[5] VA Nasonova Res Inst Rheumatol Russian Federat, Moscow, Russia
[6] Univ Lille, Lille, France
[7] Ghent Univ Hosp, Ghent, Belgium
[8] Ion Cantacuzino Clin Hosp, Dept Internal Med & Rheumatol, Bucharest, Romania
[9] Charles Univ Prague, Inst Rheumatol, Dept Rheumatol, Fac Med 1, Prague, Czech Republic
[10] Univ Ksln, Ksln, Germany
[11] Univ Calif Los Angeles, Los Angeles, CA USA
[12] Univ Granollers, Granollers, Spain
[13] Hosp Univ 12 Octubre, Madrid, Spain
[14] Univ Leeds, Leeds Inst Rheumat & Muskuloskeletal Med, Leeds, England
[15] IRCCS San Raffaele Hosp, Unit Immunol Rheumatol Allergy & Rare Dis, Milan, Italy
[16] Oslo Univ Hosp, Dept Rheumatol, Oslo, Norway
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0662
引用
收藏
页码：1323 / 1325
页数：3
相关论文
共 50 条
  • [31] Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the SENSCIS-ON Trial
    Highland, K. B.
    Vonk, M. C.
    Azuma, A.
    Mayes, M. D.
    Gahlemann, M.
    James, A.
    Kohlbrenner, V.
    Allanore, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [32] Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
    Khedoe, Padmini
    Marges, Emiel
    Hiemstra, Pieter
    Ninaber, Maarten
    Geelhoed, Miranda
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [33] Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)-The LOTUSS study
    Khanna, Dinesh
    Albera, Carlo
    Fischer, Aryeh
    Seibold, James
    Raghu, Ganesh
    Khalidi, Nader
    Chung, Lorinda
    Schiopu, Elena
    Chen, Dan
    Gorina, Eduard
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [34] SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
    Silver, R.
    RHEUMATOLOGY, 2012, 51 : I12 - I12
  • [35] Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
    Highland, Kristin B.
    Azuma, Arata
    Fischer, Aryeh
    Kuwana, Masataka
    Maher, Toby M.
    Mayes, Maureen D.
    Raghu, Ganesh
    Girard, Mannaig
    Alves, Margarida
    Gahlemann, Martina
    Distler, Oliver
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [36] Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), and the Potential Future Role of Anti-fibrotics[asterisk] in a Treatment Paradigm for SSc-ILD: A Delphi Consensus Study
    Rahaghi, F. F.
    Strek, M. E.
    Southern, B. D.
    Saggar, R.
    Hsu, V.
    Mayes, M. D.
    Silver, R. M.
    Steen, V.
    Domsic, R. T.
    Rosas, I. O.
    Kaner, R. J.
    Bhatt, N. Y.
    Flaherty, K. R.
    Gupta, N.
    Martinez, F. J.
    Morrow, L. E.
    Patel, N.
    Shlobin, O. A.
    Bernstein, E. J.
    Castelino, F. V.
    Chung, L.
    Kahaleh, B.
    Moua, T.
    Volkmann, E. R.
    Khanna, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [37] Changes in FVC in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
    Kreuter, M.
    Highland, K. B.
    Azuma, A.
    Kuwana, M.
    Maher, T. M.
    Mayes, M. D.
    Raghu, G.
    Girard, M.
    Alves, M.
    Gahlemann, M.
    Distler, O.
    PNEUMOLOGIE, 2020, 74 : S56 - S57
  • [38] Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses
    Fields, Aislin
    Potel, Koray N.
    Cabuhal, Rhandel
    Aziri, Buena
    Stewart, Iain D.
    Schock, Bettina C.
    THORAX, 2023, 78 (08) : 799 - 807
  • [39] NOCEBO EFFECT ON DIARRHOEA REPORTED IN THE SENSCIS TRIAL OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
    Distler, O.
    Highland, K.
    Azuma, A.
    Miede, C.
    Alves, M.
    Sfikakis, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1457 - 1457
  • [40] Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial
    Pope, Janet
    Proudman, Susanna
    Stevens, Wendy
    Henes, Joerg
    Simonovska, Rozeta
    Alves, Margarida
    Allanore, Yannick
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3025 - 3027
12345